Catalyst Wire Dossier Catalyst Wire Dossier

Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)

bictegravir/emtricitabine/tenofovir alafenamide · Gilead Sciences
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), covering 2025-06-26 to 2025-08-14. Get the full timeline:

Most recent: Clinical Trial Update: Real World Effectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide(BIC/FTC/TAF) in PLWH in Precarity Settings in France -IMEA073

See pricing